Justin Gainor

Alıntı yapanlar

	Hepsi	2020 yılından bugüne
Alıntılar	43866	29337
h-endeksi	88	79
i10-endeksi	227	208

7000

3500

1750

5250

20122013201420152016201720182019202020212022202320242025207 281 517 976 2049 2770 3218 3842 5087 6448 5985 5659 5251 731

Genel erişim

Tümünü görüntüle

131 makale

7 makale

genel erişime açık olanlar

genel erişime açık olmayanlar

Finansman sağlayan kuruluşun getirdiği zorunluluğa dayalı olarak

Katkıda bulunan yazarlar

subba digumarthyMassachusetts General Hospitalpartners.org üzerinde doğrulanmış e-posta adresine sahip
Aaron HataMassachusetts General Hospital, Harvard Medical Schoolmgh.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Vivek Subbiah, MDAssociate Professor, The University of Texas MD Anderson Cancer Centermdanderson.org üzerinde doğrulanmış e-posta adresine sahip
Lecia V SequistProfessor of Medicine, Harvard Medical School and Massachusetts General Hospitalpartners.org üzerinde doğrulanmış e-posta adresine sahip
Matthew HellmannMemorial Sloan Kettering Cancer Centermskcc.org üzerinde doğrulanmış e-posta adresine sahip
Joe LennerzMassachusetts General Hospital/Harvard Medical Schoolpartners.org üzerinde doğrulanmış e-posta adresine sahip
luc fribouletGustave Roussy Université Paris Saclaygustaveroussy.fr üzerinde doğrulanmış e-posta adresine sahip
Sai-Hong Ignatius OuUniversity of California Irvineuci.edu üzerinde doğrulanmış e-posta adresine sahip
Ryan SullivanMassachusetts General Hospitalmgh.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Scott J Antoniaduke.edu üzerinde doğrulanmış e-posta adresine sahip
Benjamin SolomonMedical Oncologist, Peter MacCallum Cancer Centrepetermac.org üzerinde doğrulanmış e-posta adresine sahip
Ryohei KatayamaJapanese Foundation for Cancer Researchjfcr.or.jp üzerinde doğrulanmış e-posta adresine sahip
Robert C. Doebele, MD, PhDUniversity of Colorado, Anschutz Medical Campuscuanschutz.edu üzerinde doğrulanmış e-posta adresine sahip
Gregory J. Riely, MD, PhDMemorial Sloan Kettering Cancer CenterMSKCC.org üzerinde doğrulanmış e-posta adresine sahip
Wilfried EberhardtInnere Klinik (Tumorforschung), University of Duisburg-Essenuni-duisburg-essen.de üzerinde doğrulanmış e-posta adresine sahip
Paul BaasDepartment of Thoracic Oncology, Netherlands Cancer Institutenki.nl üzerinde doğrulanmış e-posta adresine sahip
Stephen V. LiuGeorgetown Universitygunet.georgetown.edu üzerinde doğrulanmış e-posta adresine sahip
Michael LanutiAssociate Professor of Surgery, Harvard Medical Schoolpartners.org üzerinde doğrulanmış e-posta adresine sahip
Daniel SW TanNational Cancer Centre Singaporenccs.com.sg üzerinde doğrulanmış e-posta adresine sahip
Alexander DrilonMemorial Sloan Kettering Cancer Centermskcc.org üzerinde doğrulanmış e-posta adresine sahip

Takip et

Justin Gainor

Director, Center for Thoracic Cancers Program, Massachusetts General Hospital

partners.org üzerinde doğrulanmış e-posta adresine sahip

Lung cancer targeted therapy thoracic oncology immunotherapy


Başlık Alıntılara göre sırala Yıla göre sırala Başlığa göre sırala	Alıntı yapanlar Alıntı yapanlar	Yıl
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015	9288	2015
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020	1960	2020
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018	1397	2018
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633-641, 2018	1326	2018
EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ... Clinical cancer research 22 (18), 4585-4593, 2016	1210	2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016	1191	2016
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011	1155	2011
The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ... Cancer discovery 4 (6), 662-673, 2014	940	2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014	824	2014
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020	789	2020
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial AT Shaw, E Felip, TM Bauer, B Besse, A Navarro, S Postel-Vinay, ... The Lancet Oncology 18 (12), 1590-1599, 2017	711	2017
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ... Clinical cancer research 19 (15), 4273-4281, 2013	673	2013
First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ... Journal of Clinical Oncology 37 (12), 992-1000, 2019	576	2019
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial CA Shu, JF Gainor, MM Awad, C Chiuzan, CM Grigg, A Pabani, ... The Lancet Oncology 21 (6), 786-795, 2020	562	2020
Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ... New England Journal of Medicine 374 (1), 54-61, 2016	544	2016
PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li, M West, RW Tang, ... Cancer cell 28 (1), 70-81, 2015	501	2015
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ... Annals of oncology 29 (4), 959-965, 2018	491	2018
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ... Annals of Oncology 22 (12), 2616-2624, 2011	478	2011
Acquired resistance to crizotinib from a mutation in CD74–ROS1 MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ... New England Journal of Medicine 368 (25), 2395-2401, 2013	475	2013
A combinatorial strategy for treating KRAS-mutant lung cancer E Manchado, S Weissmueller, JP Morris, CC Chen, R Wullenkord, ... Nature 534 (7609), 647-651, 2016	441	2016

Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.

Makaleler 1–20

Yıllık alıntı sayısı

Mükerrer alıntılar

Birleştirilmiş alıntılar

Katkıda bulunan yazar ekleKatkıda bulunan yazarlar

Takip et

Alıntı yapanlar

Katkıda bulunan yazarlar